
PHOENIX — A new Mayo Clinic study examines the question “what would you do if you knew you are predisposed to Alzheimer’s disease?” The study, which will be published in the October edition of Mayo Clinic Proceedings, was conducted to measure attitudes concerning Alzheimer’s genetic and biomarker tests. Other studies have shown that many people would want to have tests to know if they carry the gene that causes Alzheimer’s disease. The new study showed that many people may not understand what the results mean. https://www.youtube.com/watch?v=zuUfKkWkc9Y&feature=youtu.be “About a third of the people who say they want the testing really don’t know what the implications of the tests are,” says Richard Caselli, M.D., Mayo Clinic neurologist and lead author of the study. “More education is needed before we can advocate widespread predictive testing for a disease which, at this time, we have no effective treatment.”
JACKSONVILLE, Fla. — Mayo Clinic’s stroke center in Jacksonville is the first center in Florida to receive national Comprehensive Stroke Center certification, joining an elite group of centers throughout the United States that are focused on providing advanced and complex stroke care. http://youtu.be/w520jIc54DM Centers that achieve this distinction — awarded by The Joint Commission working with the American Heart Association and the American Stroke Association — are recognized as leaders that help set the national agenda in highly specialized stroke care. The Joint Commission is the nation's oldest and largest standards-setting and accrediting body in health care.
We have all experienced the annoying, relentless and throbbing pain associated with a headache. They can slow us down or even bring us to a complete stop. However, did you know that there are several different types of headaches, and knowing the type you've got can be the first step in effectively treating it? Mayo Clinic Health System nurse practitioner Erin Pokorny takes a look at different types of headaches and shares what you can do to fight them. Tension-type headaches: These are considered to be the most common types of headaches. They are often described as dull and achy and are often brought on by stress, neck pain, missing meals and a variety of other things. Treatment options: Tension-type headaches can often be treated by over-the-counter medication, such as aspirin, ibuprofen or acetaminophen. You may also want to try alternative treatments including meditation, relaxation training and massage. Migraines: We've all heard about migraines, and we know that they’re not to be taken lightly. The pain associated with migraines is often described as throbbing and severe. Migraines are often associated with nausea, vomiting or increased sensitivity to light and sound. Pain may worsen with increased activity. Untreated, migraines can typically last anywhere from 4 to 72 hours. Treatment options: If you know the triggers for your migraines, make sure to avoid these known causes. Over-the-counter medication can help. Other treatment options include prescription medications; rest in a quiet, dark room; or a hot/cold compress to the head or neck.
Board Also Recognizes Four Recipients of Mayo Clinic Named Professorships JACKSONVILLE, Fla., and ROCHESTER, Minn. — The Mayo Clinic Board of Trustees has named Gianrico Farrugia, M.D., Mayo Clinic vice president and chief executive officer of Mayo Clinic's campus in Jacksonville, Florida. Dr. Farrugia succeeds William Rupp, M.D., who will retire from Mayo Clinic at the end of 2014. The announcement was made today at the Mayo Clinic Board of Trustees quarterly meeting where the board also recognized four recipients of Mayo Clinic named professorships. https://www.youtube.com/watch?v=pYkK-zl-gyQ Soundbites of Dr. Noseworthy are available in the downloads box. “Dr. Farrugia brings a wealth of experience to his new role,” says John Noseworthy, M.D., Mayo Clinic president and chief executive officer. “He is a physician-leader who brings to this important role a deep commitment to Mayo’s values, mission and strategic vision, along with a passion to lead and equip teams to reach more patients and strengthen Mayo Clinic’s position as a global health care leader. He has a strong commitment to continuing Dr. Rupp’s legacy of involvement and leadership in the Jacksonville community.” Dr. Farrugia has been with Mayo Clinic for more than 26 years as a physician in the Division of Gastroenterology and Hepatology and Division of Physiology and Biomedical Engineering at Mayo Clinic’s campus in Rochester, Minnesota. He is also a professor of medicine as well as physiology and biomedical engineering. Dr. Farrugia has served in numerous leadership roles at Mayo Clinic with multisite responsibilities, both in his specialty and at the organizational leadership level. He currently serves as director of the Mayo Clinic Center for Individualized Medicine and director of Mayo Clinic’s Enteric Neuroscience Program. He previously served as research chair of the Department of Medicine. In his new role, Dr. Farrugia will work with Bob Brigham, chief administrative officer in Florida, to provide leadership and direction, defining and implementing Mayo Clinic’s operational plan and continuing to expand Mayo Clinic’s leadership and reach in the Southeast and beyond.
PHOENIX — Researchers from Mayo Clinic in Arizona and Banner Sun Health Research Institute have determined that many people with an early diagnosis of Parkinson’s disease are not correctly diagnosed according to a study just published in the journal Neurology. Parkinson's disease is a progressive disorder of the nervous system that affects movement. It develops gradually, sometimes starting with a barely noticeable tremor in just one hand. But while tremor may be the best-known sign of Parkinson's, the disorder also commonly causes stiffness and slowing of movement. Additionally there are many non-movement problems including constipation, loss of the sense of smell, sleep problems, lightheadedness, urinary difficulties, depression and anxiety. Although Parkinson's disease can't be cured, medications may markedly improve symptoms. Currently, there is no accurate diagnostic test for the disease; diagnosis is made based on medical history, a review of signs and symptoms, a neurological and physical examination and by ruling out other conditions. Confirmation of the disease can only be made by performing an autopsy.
PHOENIX, Arizona – The National Institutes of Health (NIH) renewed funding for the Banner Alzheimer’s Institute (BAI) and Mayo Clinic, Phoenix, longitudinal study of the earliest changes associated with the risk of developing Alzheimer’s disease at older ages. The award, an estimated $8.3 million over the next five years, continues NIH’s long-term support of the investigation. The study, which began two decades ago, has been examining the subtle brain imaging, memory and thinking changes that occur in healthy late-middle-aged and older adults who have inherited from their parents either one, two or no copies of the apolipoprotein E (APOE4) gene, the major genetic risk factor for developing late-onset Alzheimer’s. Each additional copy of the gene significantly increases a person’s chance of developing the disease. “We are extremely grateful to the NIH and our wonderful research volunteers for their support,” said Dr. Eric M. Reiman, BAI Executive Director and one of the study’s principal investigators. “From the beginning, this study has been driven by our interest in finding treatments to prevent or end Alzheimer’s as quickly as possible, and to provide the information and tools needed to do just that.”
An online patient support community